Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAT1 | P18440 | 5/20 | 0.74 |
| ▸ | CISD1 | Q9NZ45 | 3/20 | 0.62 |
| ▸ | MYC | P01106 | 1/20 | 0.60 |
| ▸ | MAX | P61244 | 1/20 | 0.60 |
| ▸ | CA2 | P00918 | 1/20 | 0.59 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.59 |
| ▸ | MMP13 | P45452 | 2/20 | 0.57 |
| ▸ | CRHBP | P24387 | 1/20 | 0.57 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.57 |
| ▸ | MMP3 | P08254 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | PIM1 | P11309 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.55 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.54 |
| ▸ | PTP4A3 | O75365 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18103005 | 0.91 | NAT1 (0.85) | NAT1CISD1MYCMAXCA2 | |
| SCHEMBL19991267 | 0.89 | NAT1 (0.76) | NAT1CISD1MYCMAXCA2 | |
| SCHEMBL18102890 | 0.89 | NAT1 (0.76) | NAT1CISD1MYCMAXCA2 | |
| SCHEMBL18102962 | 0.89 | NAT1 (0.76) | NAT1CISD1MYCMAXCA2 | |
| SCHEMBL30250053 | 0.87 | NAT1 (0.74) | NAT1CISD1MYCMAXCA2 | |
| SCHEMBL18103006 | 0.87 | NAT1 (0.74) | NAT1CISD1MYCMAXCA2 | |
| SCHEMBL18103038 | 0.86 | NAT1 (0.91) | NAT1CISD1MYCMAXCA2 | |
| SCHEMBL19991146 | 0.86 | NAT1 (0.91) | NAT1CISD1MYCMAXCA2 | |
| SCHEMBL18102889 | 0.86 | NAT1 (0.91) | NAT1CISD1MYCMAXCA2 | |
| SCHEMBL8310946 | 0.85 | NAT1 (1.00) | NAT1CISD1MYCMAXCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10501413-B2 | Inhibitors of the Notch transcriptional activation complex and methods for use of the same | UNIVERSITY OF MIAMI (US) | 2019-12-10 | — | — | US | disclosed |
| US-20180086700-A1 | INHIBITORS OF THE NOTCH TRANSCRIPTIONAL ACTIVATION COMPLEX AND METHODS FOR USE OF THE SAME | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-03-29 | — | — | US | disclosed |
| US-20180086700-A1 | INHIBITORS OF THE NOTCH TRANSCRIPTIONAL ACTIVATION COMPLEX AND METHODS FOR USE OF THE SAME | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-03-29 | — | — | US | disclosed |
| WO-2016154255-A1 | INHIBITORS OF THE NOTCH TRANSCRIPTIONAL ACTIVATION COMPLEX AND METHODS FOR USE OF THE SAME | UNIVERSITY OF MIAMI (US) | 2016-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10501413-B2 | Inhibitors of the Notch transcriptional activation complex and methods for use of the same | NOTCH1, CBFB, HES1 | NAT1 867/4885CISD1 511/4885MYC 39/4885 |
| US-20180086700-A1 | INHIBITORS OF THE NOTCH TRANSCRIPTIONAL ACTIVATION COMPLEX AND METHODS FOR USE OF THE SAME | NOTCH1, CBFB, HES1 | NAT1 867/4885CISD1 511/4885MYC 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.